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Abstract: This study was part of monitoring an intervention aimed at developing a general practitioner
cluster (GPC) model of primary healthcare (PHC) and testing its effectiveness in delivering preventive
services integrated into the PHC system. The aim was to demonstrate whether GPC operation
could increase the percentage of drugs actually dispensed. Using national reference data of the
National Health Insurance Fund for each anatomical–therapeutic chemical classification ATC group
of drugs, dispensed-to-prescribed ratios standardized (sDPR) for age, sex, and exemption certificate
were calculated during the first quarter of 2012 (before-intervention) and the third quarter of 2015
(post-intervention). The after-to-before ratios of the sDPR as the relative dispensing ratio (RDR) were
calculated to describe the impact of the intervention program. The general medication adherence
increased significantly in the intervention area (RDR = 1.064; 95% confidence interval (CI): 1.054–1.073).
The most significant changes were observed for cardiovascular system drugs (RDR = 1.062; 95%
CI: 1.048–1.077) and for alimentary tract and metabolism-specific drugs (RDR = 1.072; 95% CI:
1.049–1.097). The integration of preventive services into a PHC without any specific medication
adherence-increasing activities is beneficial for medication adherence, especially among patients
with cardiovascular, alimentary tract, and metabolic disorders. Monitoring the percentage of drugs
actually dispensed is a useful element of PHC-oriented intervention evaluation frames.
Keywords: medication adherence; relative dispensing ratio; primary healthcare; health status
assessment; patient–physician cooperation
1. Introduction
Adherence to medications can be defined as taking medications as prescribed by healthcare
providers [1,2]. Nonadherence to medications can occur when patients delay or do not fill medication
prescriptions, do not take the desired dosage, or decide to discontinue their medications [3].
Nonadherence has been described as a global epidemic [4]. It affects various patient groups,
particularly those with chronic health conditions [5–7]. Approximately one-third of written
prescriptions are not dispensed, and approximately 50% of dispensed medications are not taken
as recommended [8–12].
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Nonadherence has a complex, multifactorial etiology [13–15]. The World Health Organization
(WHO) classifies the factors affecting medication adherence [16] as socioeconomic status (e.g., poverty,
low level of literacy, lack of social support) [17,18], medical conditions (e.g., symptom severity and
disability) [14,19], therapy-related factors (e.g., regimen complexity, duration, and side effects) [8,20],
and healthcare system specialties (e.g., patient–physician relationship, provision of services) [21,22].
The weight of this issue is reflected in the recommendation of the WHO to use the percentage of drugs
actually dispensed as a basic indicator of patient care [23].
The consequences of nonadherence are numerous. It results in accelerated progression
of the disease, avoidable complications, increased hospitalization and disability [24–26],
reduced productivity [4], a lower quality of life, and elevated mortality [13]. Evidently, it increases
healthcare costs enormously [27–33].
Several simple and complex interventions have been tried to improve adherence. Some of the
interventions that have been examined have entailed reducing the number of prescribed drugs and
adjusting the dose [27,34], giving medication reminders and improving medication schedules [35],
and employing educational strategies [8,36,37]. More complex and comprehensive strategies have
also been implemented and tested. Such strategies have included improving the patient–physician
relationship, communication, and trust; expanding and emphasizing the pharmacist role in primary
healthcare [9,27,38]; increasing awareness of the patient regarding his/her disease and medications
[39,40]; controlling medication-related side effects and performing patient habit analyses [26,41];
examining patient motivation, support, and follow-up [8,13,14,42]; and keeping the patient in the core
of the healthcare process and considering his/her feedback [43].
Since adherence is a multifactorial issue, experiences with the limited effectiveness of
unimodal interventions, which target one aspect of nonadherence, are not surprising [40,44].
Multifaceted, comprehensive approaches with strategies designed and tailored to suit individual
patients or groups have been found to be the most effective [12,13,45]. Interventions delivered by
a number of health professionals, including physicians, pharmacists, nurses, and community healthcare
workers, have been proven to be effective in increasing adherence [46–49].
Additionally, strategies must be simple enough to put into daily practice [50]. Approaches that
focused on patient follow-up have been found to be very effective [51,52]. A key issue is the integration
of approaches that encourage adherence into a healthcare system and services [53].
Unfortunately, there is no gold standard for a comprehensive approach that can be used to
enhance adherence [54]. One meta-analysis of many interventions indicated an increase in adherence
magnitude from 4% to 11% [10].
Objectives
Our investigation was part of monitoring the “Public Health-Focused Model Program for
Organizing Primary Care Services Backed by a Virtual Care Service Center” [55], which is aimed at
developing a general practitioner cluster (GPC) model of primary healthcare (PHC) and testing its
effectiveness in delivering preventive services integrated into the PHC system. The goal of this model,
in line with the recommendations of the WHO [56], was to complete a traditional core PHC team of
one GP and one nurse with other health professionals who were formerly not available at the PHC
level [57,58]. The GPC is a multimodal PHC intervention based on (1) organized, population-level
general health checks implemented by public health experts and nurses to explore unmet needs,
(2) follow-ups of at-risk patients by providing care via the extended PHC team, (3) new services and
nonmedical activities (counseling by a dietitian and psychologist, treatment by a physiotherapist,
supporting patient–GP cooperation with mediators), and (4) supervision by a GP.
Our study aimed to demonstrate whether the GPC operation, which aims to improve the general
effectiveness of a PHC, could increase primary adherence (the percentage of drugs actually dispensed),
thereby reflecting improvement in the quality of patient–GP collaboration.
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2. Methods
2.1. Setting
Typical Hungarian primary healthcare teams (composed of one general practitioner and one
practice nurse) were invited to form GPCs in 2012. The core team was completed with other health
professionals. The GPCs were designed to offer preventive services and health promotion interventions
in addition to the traditionally given curative, acute, and emergency services. GPC composition
and operation rules are summarized elsewhere in detail [57]. Briefly, six core primary healthcare
teams formed one GPC. Each GPC employed 1 dietician, 1 physiotherapist, 1 health psychologist,
1 community nurse, 2 public health specialists, and 12 health mediators. Finally, 4 GPCs were established.
New services of the program were launched in 2014 after elaboration on care protocols, the training of
staff, and the creation of new infrastructures. All adults over 18 years of age whose GPs were involved in
the program were called to participate in an organized health status assessment performed by a public
health specialist and a community nurse. Details of the assessment have been described earlier [59,60].
The importance of the risk factors and/or conditions identified by the health status assessment was
evaluated in a medical risk assessment carried out by a GP. Further, new services of the program
that were not available formerly at the level of PHC included the following: GPs referred patients to
lifestyle counseling and treatment sections provided by physiotherapists, dieticians, psychologists,
and public health specialists to address risk factors and conditions and improve health knowledge and
adherence to medical and health professionals’ advice [61].
2.2. Data Sources
Data on the number of drugs prescribed by the GPs and dispensed to patients during the first
quarter of 2012 (2012Q1, representing the before-intervention status) and the third quarter of 2015
(2015Q3, representing the post-intervention status) were provided by the National Health Insurance
Fund, which is the national institution that contracts with each general medical practice (GMP) of
Hungary. The number of prescriptions and the number of dispensed prescriptions were the subjects
of the analysis. GMP-specific data were stratified by sex, age group (18–19, 20–24, 25–29, . . . , 75–79,
80–84, 85–X years), and eligibility for an exemption certificate (through which socioeconomically
disadvantaged patients who require long-term care can get drugs and medical devices free of charge).
This kind of database was prepared for each anatomical–therapeutic chemical classification (ATC) group
of drugs [62]. Groups of “antineoplastic and immunomodulating agents” and “antiparasitic products,
insecticides, and repellents” were not analyzed because these drugs are not typically prescribed by
GPs according to Hungarian rules.
2.3. Statistical Analysis
The amount of prescribed and dispensed drugs and the percentage of dispensed prescribed drugs
(dispensed-to-prescribed ratio, DPR) were calculated for the aggregated intervention population and
for the whole country by ATC group and by sex, age group, and eligibility for an exemption certificate
for the 2012Q1 and the 2015Q3 periods. We used the DPR as a key indicator of patient care to assess
primary adherence to prescribed medications [23].
The sex-, age-, and exemption certificate-specific number of written prescriptions for the
intervention population and national reference DPRs were used to compute the expected number of
dispensed prescriptions for the intervention population (by summarizing the expected number
of dispensed prescriptions across the strata). The ratio of the observed number of dispensed
prescriptions and the total expected number of dispensed prescriptions was computed as the
intervention population-specific standardized DPR (sDPR) for each ATC group.
The ratio of 2015Q3-specific and 2012Q1-specific sDPRs as the relative dispensing ratio (RDR)
was calculated for each ATC group to describe the impact of the intervention program on the DPR.
Int. J. Environ. Res. Public Health 2019, 16, 3797 4 of 13
The statistical evaluation was carried out using a 95% confidence interval (95% CI) of the measures.
SPSS version 20 was used to complete the calculation processes.
2.4. Patient and Public Involvement
Although patients’ needs and public health importance were investigated in this study,
the development of the research question and study design was carried out without involvement of
the patients and the public. Because aggregated patient data were processed in the statistical works,
the analyses did not require the active contribution of patients or their representatives.
3. Results
There were 33,101 adults older than 18 years in the intervention population. The age distribution
of the intervention population was similar to the national reference before the intervention, but it
deviated from the national reference in a statistically significant manner by the end of the study period.
There was a statistically significant, but not important, overrepresentation of males and individuals
eligible for an exemption certificate in the intervention population. The reference population of adult
Hungarians totaled 7,886,662 and 7,745,112 in the first quarter of 2012 and in the third quarter of 2015,
respectively (Table 1).
Table 1. Demographic composition of the population in the intervention area and Hungary.
Patient Characteristics Intervention Area % (N) Hungary % (N) p-Value *
First quarter of 2012
Age group (years)
18–44 46.1% (15,265) 46.5% (3,667,334)
0.34045–64 33.2% (10,973) 33.0% (2,602,749)
65 and above 20.7% (6863) 20.5% (1,616,579)
Sex
Male 47.9% (15,855) 46.7% (3,679,137)
<0.001Female 52.1% (17,246) 53.3% (4,207,525)
Exemption certificate Yes 5.8% (1933) 3.2% (251,027) <0.001No 94.2% (31,168) 96.8% (7,635,635)
All together 100% (33,101) 100% (7,886,662) -
Third quarter of 2015
Age group (years)
18–44 45.4% (14,690) 44.6% (3,451,254)
<0.00145–64 32.5% (10,499) 33.3% (2,578,267)
65 and above 22.1% (7133) 22.2% (1,715,591)
Sex
Male 47.8% (15,449) 46.7% (3,619,811)
<0.001Female 52.2% (16,873) 53.3% (4,125,301)
Exemption certificate Yes 5.3% (1718) 2.5% (194,678) <0.001No 94.7% (30,604) 97.5% (7,550,434)
All together 100% (32,322) 100% (7,745,112) -
* Chi-squared test.
More than half of this target community (N = 18,833, 57.9%) participated in an organized health
status assessment by the end of 2015Q3. Most of them (95.0%) were referred to GPC-employed health
professionals. Among participants, females (the proportion of females among health check participants
was 59.0%) and older (the proportions of 18–44-, 45–64-, and 65+-year-old participants were 39.2%,
37.5%, and 23.3%, respectively) subjects were overrepresented.
The DPR in Hungary was 69.3% in the first quarter of 2012 and decreased to 60.8% by the third
quarter of 2015. This reduction was observed in each studied socioeconomic stratum and in each
studied ATC group. All of these reductions proved to be statistically significant using a chi-squared
test. The DPR difference between males and females was negligible in both study periods. Being over
65 proved to positively influence the DPR, while the DPR was minimal among middle-aged patients
and the DPR was higher among patients with exemption certificates than among those without
exemption certificates in the studied periods. The highest DPR was observed for anti-infectives for
systemic use (DPR2012Q1 = 80.1%, DPR2015Q3 = 76.1%). The minimum DPR was registered for the
group of various drugs in 2012Q1 (DPR = 57.6%) and for cardiovascular system drugs in 2015Q3
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(DPR = 55.3%). Differences between DPRs before and after the intervention were statistically significant
across sociodemographic and ATC groups (Table 2).
Table 2. The proportion of dispensed medications prescribed by general practitioners (GPs) in Hungary
in the first quarter of 2012 (before-intervention) and in the third quarter of 2015 (after the program
implementation) by patient sociodemographic characteristic and anatomical–therapeutic chemical
classification (ATC) drug group.
Patient Characteristics and
ATC Groups
Prescriptions Before Intervention Prescriptions After Intervention
Written Dispensed
Dispensed
Ratio
(%)
Written Dispensed DispensedRatio (%) p-Value *
Age group (years)
18–44 2,879,000 1,952,263 67.8% 2,525,076 1,529,643 60.6% <0.001
45–64 11,732,996 7,889,604 67.2% 10,874,787 6,369,987 58.6% <0.001
65 and
above 15,190,426 10,822,025 71.2% 14,899,896 9,304,872 62.4% <0.001
Sex
Male 11,689,243 8,051,849 68.9% 11,158,720 6,711,249 60.1% <0.001
Female 18,113,179 12,612,043 69.6% 17,141,039 10,493,253 61.2% <0.001
Exemption
certificate
Yes 3,499,275 2,804,373 80.1% 2,709,909 2,054,121 75.8% <0.001
No 26,303,147 17,859,519 67.9% 25,589,850 15,150,381 59.2% <0.001
Alimentary tract and
metabolism 4,831,608 3,504,498 72.5% 4,596,768 3,042,485 66.2% <0.001
Blood and blood-forming
organs 2,187,096 1,636,426 74.8% 1,970,831 1,333,257 67.6% <0.001
Cardiovascular system 15,311,478 10,057,565 65.7% 14,642,073 8,094,617 55.3% <0.001
Dermatologic 289,326 189,229 65.4% 300,258 176,043 58.6% <0.001
Genitourinary system and sex
hormones 210,643 152,318 72.3% 219,692 143,770 65.4% <0.001
Systemic hormonal
preparations 323,519 244,649 75.6% 354,554 259,049 73.1% <0.001
Anti-infectives for systemic use 1,208,603 968,386 80.1% 666,892 507,756 76.1% <0.001
Musculoskeletal system 1,851,092 1,324,670 71.6% 2,093,343 1,389,095 66.4% <0.001
Nervous system 1,921,312 1,419,382 73.9% 1,845,835 1,255,821 68.0% <0.001
Respiratory system 1,488,397 1,042,395 70% 1,448,618 901,644 62.2% <0.001
Sensory organs 128,978 95,371 73.9% 97,004 63,204 65.2% <0.001
Various 50,370 29,003 57.6% 63,891 37,761 59.1% <0.001
All together 29,802,422 20,663,892 69.3% 28,299,759 17,204,502 60.8% <0.001
* Chi-squared test.
The registered number of prescriptions and dispensed prescriptions in the intervention population
was 134,470 and 98,213, respectively, for 2012Q1. The observed DPR before the intervention was 73.0%.
The influence of sex and age on the DPR was moderate, while the difference between DPRs for patients
eligible and not eligible for an exemption certificate was statistically significant. The ATC-specific
DPR variability by ATC group was also statistically significant. The highest and lowest DPRs were
observed for systemic hormonal preparations (81.8%) and cardiovascular system drugs (68.8%),
respectively (Table 3).
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Table 3. The proportion of dispensed medications prescribed by GPs in the intervention area before and
after the program implementation by patient sociodemographic characteristic and ATC drug group.
Patient Characteristics and ATC
Groups
Prescriptions Before
Intervention Prescriptions After Intervention
Change of
Dispensed Ratio
Written Dispensed
Dispensed
Ratio
(%)
Written Dispensed DispensedRatio (%) p-Value *
Age group (years)
18–44 15,808 11,475 72.6% 15,670 10,425 66.5% <0.001
45–64 55,673 40,197 72.2% 54,909 36,756 66.9% <0.001
65 and
above 62,989 46,541 73.9% 63,110 44,700 70.8% <0.001
Sex
Male 51,818 37,999 73.3% 51,349 35,103 68.4% <0.001
Female 82,652 60,214 72.9% 82,340 56,778 69.0% <0.001
Exemption certificate Yes 24,372 20,656 84.8% 22,505 18,617 82.7% 0.077
No 110,098 77,557 70.4% 111,184 73,264 65.9% <0.001
Alimentary tract and metabolism 20,238 15,326 75.7% 20,536 15,336 74.7% 0.356
Blood and blood-forming organs 10,498 8209 78.2% 9908 7569 76.4% 0.272
Cardiovascular system 64,495 44,383 68.8% 65,030 40,319 62.0% 0.000
Dermatologic 1524 1141 74.9% 1695 1189 70.1% 0.231
Genitourinary system and sex
hormones 835 661 79.2% 1098 834 76.0% 0.552
Systemic hormonal preparations 1662 1360 81.8% 1796 1459 81.2% 0.886
Anti-infectives for systemic use 6392 5212 81.5% 3616 2906 80.4% 0.641
Musculoskeletal system 10,083 7627 75.6% 11,773 8679 73.7% 0.215
Nervous system 9192 7133 77.6% 9408 7302 77.6% 0.993
Respiratory system 8667 6530 75.3% 8052 5767 71.6% 0.033
Sensory organs 580 445 76.7% 535 369 69.0% 0.249
Various 304 186 61.2% 242 152 62.8% 0.851
All together 134,470 98,213 73.0% 133,689 91,881 68.7% <0.001
* Chi-squared test to compare dispensed ratio before and after the intervention.
The DPR for after the intervention period was 68.7% (133,689 prescriptions; 91,881 dispensed).
The impact of sex and the eligibility for an exemption certificate showed no change. However, the age
group effects widened considerably. The ranges of the ATC-specific DPR variability and the extreme
groups did not change (from the lowest DPR of 62.0% for cardiovascular system drugs to the highest
DPR of 81.2% for systemic hormonal preparations).
According to the sDPRs, medication adherence was slightly higher in the intervention area
than in Hungary in general for each ATC group. The before-intervention sDPR of 1.042 increased
to 1.108 by the 2015Q3 period. This change in sDPR proved to be significant (RDR = 1.064; 95%
CI: 1.054–1.073; p < 0.001) and corresponded to 5033.2 excess dispensed prescriptions. In the ATC
groups, the most significant changes were observed for cardiovascular system drugs (RDR = 1.062;
95% CI: 1.048–1.077; p < 0.001) and for alimentary tract and metabolism-specific drugs (RDR = 1.072;
95% CI: 1.049–1.097; p < 0.001), corresponding to 2143.5 and 1001.2 excess dispensed prescriptions,
respectively. Significant improvement was observed for nervous system drugs (RDR = 1.082; 95%
CI: 1.047–1.118; p < 0.001), blood and blood-forming organ drugs (RDR = 1.077; 95% CI: 1.044–1.111;
p < 0.001), and musculoskeletal (RDR = 1.041; 95% CI: 1.010–1.074; p = 0.010) drugs (Table 4).
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Table 4. Changes in standardized dispensed-to-prescribed ratio (sDPR) in the intervention area and
the number of excess dispensed prescriptions attributable to the program’s implementation (stratified
by ATC drug group).
ATC Group Before Intervention After Intervention Change of sDPR
sDPR (O/E) * ExcessDispensing sDPR (O/E)
Excess
Dispensing RR ** (95% CI)
Excess
Dispensing p-Value
Alimentary tract
and metabolism
1.035
(15,326/14,809.5) 516.5
1.11
(15,336/13,818.3) 1517.7
1.072
(1.049–1.097) 1001.2 <0.001
Blood and
blood-forming
organs
1.042
(8209/7878.5) 330.5
1.122
(7569/6745.6) 823.4
1.077
(1.044–1.111) 492.9 <0.001
Cardiovascular
system
1.035
(44,383/42,880.5) 1502.5
1.099
(40,319/36,673) 3646
1.062
(1.048–1.077) 2143.5 <0.001
Dermatologic 1.134(1141/1006.4) 134.6
1.168
(1189/1017.7) 171.3
1.031
(0.950–1.118) 36.7 0.468
Genitourinary
system and sex
hormones
1.087
(661/608) 53
1.154
(834/722.4) 111.6
1.062
(0.959–1.176) 58.6 0.249
Systemic hormonal
preparations *
1.081
(1360/1258.1) 101.9
1.108
(1459/1316.8) 142.2
1.025
(0.952–1.104) 40.3 0.513
Anti-infectives for
systemic use
1.011
(5212/5157.1) 54.9
1.052
(2906/2763.2) 142.8
1.041
(0.994–1.089) 87.9 0.086
Musculoskeletal
system
1.042
(7627/7320.2) 306.8
1.085
(8679/7999.9) 679.1
1.041
(1.010–1.074) 372.3 0.010
Nervous system 1.045(7133/6828.7) 304.3
1.13
(7302/6461.4) 840.6
1.082
(1.047–1.118) 536.4 <0.001
Respiratory system 1.147(6530/5693.2) 836.8
1.128
(5767/5113.5) 653.5
0.983
(0.949–1.019) -183.4 0.351
Sensory organs 1.031(445/431.6) 13.4
1.048
(369/352.1) 16.9
1.017
(0.886–1.167) 3.6 0.817
Various 1.057(186/176.1) 9.9
1.049
(152/144.9) 7.1
0.993
(0.801–1.230) -2.9 0.950
All together 1.042(98,213/94,275.9) 3937.1
1.108
(91,881/82,910.7) 8970.3
1.064
(1.054–1.073) 5033.2 <0.001
* (O/E): observed and expected number of dispensed drugs. ** RR = sDPRafter/sDPRbefore.
4. Discussion
4.1. Main Findings
In this study, we estimated the impact of a PHC-level, multifaceted intervention on the
enhancement of primary adherence to prescribed medications. The overall increase in the age-,
sex-, and exemption certificate eligibility-standardized dispensed percentage of prescribed medications
was 6%. Indeed, we observed that the percentage of drugs actually dispensed declined over time
in both the intervention area and in Hungary. However, the decline was sharper in Hungary in
general compared to that in the intervention area. This improvement was a secondary impact of
activities conducted within the project, which aimed primarily to improve health outcomes through
the integration of new primary, secondary, and tertiary preventive services into the PHC system.
The achieved improvement of 6% was somewhat modest, but it fit within the range of 4% to 11%
reported in other studies [10,63]. It seems probable that completing the GPC intervention with the
targeted training modalities would further enhance these achievements.
The most important impacts were observed for cardiovascular system drugs (42.6% excess of
dispensed prescriptions) and alimentary tract and metabolism-specific drugs (19.9% excess of dispensed
prescriptions), which showed that individuals with diseases of higher prevalence and demand on
the PHC workforce were the most responsive to the intervention. This finding suggests that more
intensive care for patients plays a key role in improving primary adherence. The nonspecific nature
of the intervention with respect to medication adherence is supported by the fact that significant
improvements with smaller impacts were also observed in the case of nervous system drugs (10.7%
of excess dispensed prescriptions), blood and blood-forming organ drugs (9.8% of excess dispensed
prescriptions), and musculoskeletal drugs (7.4% of excess dispensed prescriptions).
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These findings are in good concordance with the well-known fact that the patient–provider
relationship is an important predictor of adherence [64,65]. Improved collaboration entails mutual
understanding and creates trust [66–69] that affects patients’ beliefs about medications and enhances
adherence [70–72]. In addition, this improved patient–physician relationship may give patients a more
active role in the therapeutic process and in decision-making, taking into account patient perspectives
and eventually leading to enhanced adherence [73].
An important condition of the study was that the DPRs from 2012Q1 and those from the last
available period of 2015Q3 showed remarkable differences in Hungary. The causes of the national
reference data change—controlled for by the study design—were not investigated, but they may be
attributable to seasonal effects, taking into consideration that 2012Q1 included January, February,
and March while 2015Q3 included July, August, and September. They may also be attributable to
a reduced number of patients with an exemption certificate.
4.2. Implications
In fact, there was no training in the GPC intervention to improve the healthcare professionals’
ability to educate patients, support patients psychologically, or organize family support in order to
improve patients’ medication adherence. Our results confirm that an improvement in client–physician
cooperation (e.g., by integrating missing preventive services into a PHC) leads to improved medication
adherence without intentionally targeting this change. Therefore (not debating the importance of
targeted programs to medication adherence [63]), our observations suggest that medication adherence
should be systematically checked by DPR-like indicators in the case of any PHC development project,
since a positive impact on medication adherence can be a secondary effect of any intervention that
influences cooperation between patients and health professionals [74]. It seems that DPR-like measures
can be used as indicators for the effectiveness of cooperation between clients and health professionals.
Exploitation of this opportunity seems to be especially important, since medical doctors have no
proper information on medication nonadherence, and they underestimate the frequency of it [75,76].
Additionally, medical doctors express their need for feedback, and they would like to know whether
their practice needs to be modified or not [77].
Furthermore, currently available information technology (IT) could produce indicators for routine
monitoring without exceptional costs, as demonstrated by our investigation. This could support
general benchmarking activities.
4.3. Strengths and Limitations
This study was a before–after analysis. Therefore, potential confounding factors (socioeconomic
status of participants, symptom severity and disability among participants, available therapeutic tools)
that were not taken into account in the statistical analysis could be considered constants. Using national
reference data, the design of the study made it possible to control for factors that could potentially
influence the DPR and change throughout the country without identifying and quantifying them.
Without this design element, the study could not have been informative regarding the effect of GPCs
on medication adherence.
Although dispensing medications is an initial step in the therapeutic process, it cannot fully
determine whether the patient really uses the medication and follows physician instructions properly.
A person-level linkage between the actually used extra services of a GPC, drug consumption, and
data on prescribed and dispensed medications was not feasible in our investigation. Considering that
more than half of the target population participated in the health status assessment by the end of the
study period and that practically all of these participants were involved in GPC-specific extra care,
approximately half of the target population produced improvement in the intervention area-specific
DPR. The observed impact on medication adherence was an underestimation of the real influence
of a GPC. Consequently, this validity issue did not jeopardize the conclusion on the effectiveness of
the intervention.
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Because we carried out indirect standardization according to the sociodemographic status of
subjects, where the demographic strata-specific redemption could not be quantified, our analysis
could not identify the strata, which were responsible for the 6% increase in the redemption intention.
Furthermore, mechanisms eliciting the reported enhancement of adherence were not studied in our
investigation, since adherence enhancement was not among the program’s objectives and the monitoring
did not cover this question. Additional investigations are needed to identify the beneficial changes.
5. Conclusions
Altogether, our observations demonstrate that the integration of preventive services into
a PHC (by ensuring the necessary capacity and elaborating on new protocols) is beneficial for
medication adherence, especially among patients with cardiovascular, alimentary tract, and metabolic
disorders. The 6% enhancement in the percentage of drugs actually dispensed that was achieved
in our GPC-based intervention without any specific medication adherence-increasing activities
corresponded to, but did not exceed, the published range of achievements of targeted and multifaceted
adherence-increasing interventions.
Considering the high impact and the multifactorial (but not properly explored) nature of medication
adherence, monitoring the percentage of drugs actually dispensed seems to be a rational element of
PHC-oriented intervention evaluation frames. Moreover, this indicator should be used in general
monitoring of PHCs to support benchmarking. Our findings emphasize that the WHO recommendation
for applying the percentage of drugs actually dispensed as a routine indicator should be considered
more seriously: the measure of “percentage of drugs actually dispensed” could be a useful indicator of
the effectiveness of client–PHC provider collaboration.
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